Kornimate/medical-research-clean huggingface dataset:
predictors of chronic kidney disease among type 2 diabetic patients in assiut university hospitals

Conditions: Type 2 Diabetes With Renal Manifestations

Summary: predictors of chronic kidney disease among type 2 diabetic patients in assiut university hospitals.

globally, the total number of people with diabetes is estimated to increase from 415 million (8.8%) in 2015 to 642 million (10.4%) in 2040, with the largest alterations expected to occur in the urban population of low- to middle-income countries (lmics)1. of them, type 2 diabetes mellitus (t2dm) accounts for more than 90% of people with diabetes2,3. by 2040, the difference worldwide is projected to broaden, with 477.9 million affected people living in urban areas and 163.9 million in rural areas1. it has been postulated that the burden of diabetes and its complications in the lmics may be contributed by the economic development and rapid urbanisation via increased caloric intake and the adoption of a sedentary lifestyle2,4,5. more importantly, the most striking demo graphic change to diabetes prevalence in global terms also seems to be related to the growth of the proportion of the elderly population6. despite rates of diabetes-related complications such as cvds decreasing significantly in the past two decades, it has not translated nearly as well as kidney complications7. approximately 10% of deaths in people with t2dm are attributable to kidney failure8. it is well-established that diabetes-related chronic kidney disease (ckd) is the leading cause of end-stage kidney disease (eskd) in t2dm patients worldwide9,10. in our study, we aim to identify and classify patients attending diabetic outpatient clinic with both ckd and

Eligibility criteria:
inclusion criteria: - patients with t2dm aged 18 years or older. for patients whom egfr values \< or =60 ml/min/1.73m2. patient with type 2 dm and esrd on regular hd with duration less than 1 year exclusion criteria: having kidney transplantation incomplete data on glycemic control. patients with type 2 dm and esrd on regular hd with duration more than 1 year. pregnant woman. patients with advanced comorbides(cardiac, hepatic,
tms for cognitive decline in aging and preclinical ad

Conditions: Prodromal Alzheimer&#39;s Disease; Preclinical Alzheimer&#39;s Disease; Healthy Aging; Cognitive Decline

Summary: in this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical alzheimer's disease. this study will use a form of non-invasive brain stimulation called repetitive transcranial magnetic stimulation (rtms). rtms will slightly alter activity in an area of your brain that controls cognition. changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with magnetic resonance imaging (mri). participants will come in for one baseline visit followed by 10 days of daily rtms study visits (monday through friday) and an evaluation visit. then, there will be a 2-week break. after this break, they will return for another baseline visit, an additional 10 days of rtms, and a final evaluation visit.


Eligibility criteria:
inclusion criteria: 1. between the ages of 40-99 2. native english speakers 3. willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points 4. cognitively normal older adults and individuals with preclinical alzheimer's disease will be included. exclusion criteria: 1. history of head trauma involving loss of consciousness or alteration in consciousness 2. another major neurologic or psychiatric condition 3. known presence of a structural brain lesion (e.g. tumor, cortical infarct) 4. any contraindication to mri, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body 5. longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed 6. any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol. 7. unwilling to return for follow-up, undergo neuropsychological testing, tms, and mr imaging 8. history of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.). 9. subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder. 10. subjects currently taking, or plan to take, medications which are highly epileptogenic. these include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.

Keywords: transcranial magnetic stimulation
depression and interleukin-6 production in patients with ovarian epithelial cancer

Conditions: Depression; Fatigue; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders

Summary: rationale: measuring levels of interleukin-6 and depression may help doctors understand the relationship between interleukin-6 and depression. it may also help the study of cancer in the future. purpose: this clinical trial is studying depression and interleukin-6 production in patients with ovarian epithelial cancer.

objectives: * correlate tumor production of interleukin (il)-6, serum levels of il-6, and il-6 coding or promoter single nucleotide polymorphisms with il-6 protein production in patients with ovarian epithelial cancer. * correlate tumor culture supernatant, ascitic fluid, and/or serum il-6 level with levels of depression and/or anxiety in these patients to determine whether catecholamines or cortisol may alter production of il-6 by cultured ovarian cancer cells. * determine the effects of neuroendocrine activity on modulation of il-6 production in these patients. * compare immune response to autologous tumor tissue in "mlr-like" reactions between tumor and peripheral blood mononuclear cells in vitro. * correlate the levels of immunologic response with relapse and/or survival times, clinical response to ca 125 antibody treatment (e.g., in a pre- vs post-therapy sampling framework), and il-6 parameters in these patients. * determine the use of epitope prediction bioinformatic tools in consultation with coulter to set up a major histocompatibility complex (mhc) tetramer assay for assessing cytotoxic t lymphocyte levels in peripheral blood from these patients. * determine the incidence of herpes virus infections in these patients. outline: this is a pilot study. before and after cytoreduction surgery, patients complete multiple questionnaires, including beck depression inventory, positive \& negative mood state, fatigue symptom inventory, revised neo personality inventory, cope, sf-36, pittsburgh sleep quality inventory, and mental adjustment to cancer, to assess depression and coping mechanisms. blood samples are collected at baseline and on postoperative days 1-4 and analyzed for interleukin (il)-6, c-reactive protein, herpes simplex virus-8 (hsv8), epinephrine, adrenocorticotropic hormones, and cortisol. ovarian carcinoma tissue samples and peritoneal fluid are also collected and evaluated for production and utilization of il-6, hsv8, and autonomic nervous system and hypothalamic-pituitary-adrenal activity. projected accrual: approximately 36 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of ovarian epithelial cancer * scheduled to undergo cytoreduction of ovarian tumor patient characteristics: * able to communicate with the investigator prior concurrent therapy: * see disease characteristics

Keywords: depression fatigue sleep disorders psychosocial effects of cancer and its treatment ovarian epithelial cancer
cardiovascular health improvement project

Conditions: Aortic Aneurysm; Aortic Dissection; Bicuspid Aortic Valve (BAV); Heart Failure; Cardiovascular Diseases

Summary: the goal of this project is to establish a biobank of clinical information, dna, plasma, and aortic tissue samples from patients with cardiovascular disease as well as healthy controls.

the goal of this project is to establish a biobank of clinical information, dna, plasma, and aortic tissue samples from patients with cardiovascular disease as well as healthy controls. the aims of the study are to collect biological specimens (blood, plasma, serum, aortic tissue) and family history; establish a biobank, establish a comprehensive database with information from consented patients, and provide researchers with high quality well annotated dna samples with demographic and clinical information.

Eligibility criteria:
inclusion criteria: * any patient over the age of 18 who is able/willing to give informed consent * patients \<18 years of age with parental consent and assent (if assent is applicable for their age) * diagnosis of: * aortic pathology potentially due to a known or suspected inherited condition * idiopathic aortic aneurysm * interesting of novel vascular pathology in the aorta or main branches * family history of aortic or vascular disease * other cardiovascular disease * healthy controls with no apparent cardiovascular disease exclusion criteria: - not willing or able to sign the consent

Keywords: aorta abdominal aortic aneurysm (aaa) thoracic aortic aneurysm (taa) bicuspid aortic valve (bav) aortic dissection
physical activity pathway for patients with osteoarthritis in primary care (oa-pcp)

Conditions: Osteoarthritis

Summary: this is a multi-phase study that will develop and test an osteoarthritis (oa) primary care physical activity care pathway (oa-pcp), a scalable intervention that includes: 1) a practical process for physical inactivity screening in primary care, 2) a brief, tailored physical activity (pa) counseling intervention via telephone, 3) connection of patients with community programs and other resources to support pa, and 4) follow-up with patients to deliver additional appropriate counseling and referrals to pa resources.

this study will be a single group pilot trial of the oa-pcp. the feasibility and acceptability of the oa-pcp will be assessed among n=60 patients with hip and knee oa in two primary care clinics. all patients in the trial will participate in the oa-pcp and will complete assessments at baseline and 4-month follow-up. feasibility metrics will include rates of recruitment, intervention engagement and retention; acceptability will be assessed from both patients and health care providers.

Eligibility criteria:
inclusion criteria: * physician diagnosis of knee or hip oa * current joint symptoms * current weekly physical activity \<150 minutes per week. exclusion criteria: * pain in chest when performing physical activity * pain in chest when not performing physical activity * loss of balance because of dizziness or loss of consciousness * recommendation from doctor to only perform physical activity under medical supervision * no documented diagnosis of knee or hip oa * dementia or other memory loss condition * active diagnosis of psychosis * active substance abuse disorder * total knee or hip replacement surgery, meniscus tear, ligament tear, or other significant lower extremity injury or surgery in the last 6 months * severe hearing or visual impairment * serious/terminal illness as indicated by referral to hospice or palliative care * unstable angina * hospitalization for cardiovascular event in last 6 months * history of ventricular tachycardia * unstable chronic obstructive pulmonary disease (2 hospitalizations within the previous 6 months and/or on oxygen) * stroke with moderate to severe aphasia * recent history (last 6 months) of three or more falls

Keywords: osteoarthritis knee osteoarthritis hip osteoarthritis
efficacy of azithromycin to prevent bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation

Conditions: Malignant Hematological Diseases

Summary: the occurrence of bronchiolitis obliterans syndrome (sbo) after allogeneic hematopoietic stem cell transplantation (hsct) is considered to be a chronic pulmonary graft versus host disease (gvhd) that is associated with significant mortality and morbidity. the reported incidence of sbo varies from 6 to 26% of allogeneic hsc recipients and is usually diagnosed within 2 years after transplantation. the diagnosis of sbo relies on the occurrence of a new airflow obstruction identified during pulmonary function testing, and the definition differs between studies. currently, no curative immunosuppressive treatment is available, and recent data suggest that the use of these treatments, especially corticosteroids, should be limited because of their toxicity. the impairment of lung function parameters is likely caused by fibrous small airway lesions. few data on the pathogenesis of sbo after allogeneic hsct are available. several hypotheses are based on the occurrence of sbo during chronic graft rejection after lung transplantation, which shares many clinical and histopathological similarities with sbo after allogeneic hsct. one hypothesis is that the first step leading to sbo is lung epithelium injury. sbo is then identified as an alloimmune reaction with only one clearly identified risk factor: extrathoracic chronic gvhd. due to their anti-inflammatory and immunomodulatory properties, recent data suggest that low-dose macrolides may be effective at preventing sbo after lung transplants. this well-tolerated treatment may be useful for preventing sbo after allogeneic hsct. the objective of this phase 3 multicentre randomized, double-blinded, clinical trial is to evaluate the efficacy of azithromycin in preventing bo syndrome after allogeneic hsct in patients with malignant hematological diseases.


Eligibility criteria:
inclusion criteria: * patients\> 16 years old * experimenting an allogeneic hsct for a hematologic malignancy * pre-transplantation pulmonary function testing * with written informed consent exclusion criteria: * allergy or intolerance to azithromycin, macrolides or ketolide or excipient * prolonged corrected qt (qtc) interval (\>450 msec) * taking medications that prolong the qtc interval (cisapride, ergotamine, dyhydroergotamine) * taking ergotamine and dyhydroergotamine due to the risk of ergotism * family history of a prolonged qtc interval. * history of congestive heart failure * taking colchicine severe liver insufficiency • history of infection due to atypical mycobacteria

Keywords: hematopoietic stem cell transplantation pulmonary non-infectious complications bronchiolitis obliterans syndrome
a retrospective case series study for acute abdomen in general surgery ward

Conditions: The Study Was Aimed to Assessing the Clinical Profile of Acute Abdomen and Their Frequency According to Age and Sex

Summary: the acute abdomen is a clinical situation in which an acute an change in the condition of intra-abdominal organ, commonly attached to inflammation or infection need urgent and correct diagnosis .

a special data collection sheet designed to collect data regarding the diagnosis, age and sex from the profile of patients retrospectively. data entry was performed by using microsoft excel and all the data were analysed by spss.

Eligibility criteria:
inclusion criteria: * all of patients with acute abdomen that is admitted in general surgery ward of aliabad teaching hospital. exclusion criteria: * traumatic abdominal injury, abdominal pain due to urological and gynaecological origin.

Keywords: acute abdomen, abdominal pain, acute appendecitis, intestinal obstruction
to document the effectiveness of bont-a injection in adult subjects with upper limb spasticity following stroke

Conditions: Muscle Spasticity

Summary: the purpose of the study is to assess the responder rate as defined by the achievement of the primary goal from the goal attainment scale following one bont-a injection cycle in accordance with routine practices.


Eligibility criteria:
inclusion criteria: * upper limb spasticity following stroke * at least a 12-week interval between the last injection (bont-a or bont-b) and inclusion * decision already been agreed to inject bont-a * agreement with the subject on goal setting exclusion criteria: * contraindications to any bont-a preparations
pilot evaluation of hospice decision support tools

Conditions: Hospice; End-of-life Decision Making; Hospice Decision Making

Summary: the goal of this project is to determine the feasibility and acceptability of a hospice decision aid among a diverse population of older adults at multiple stages of illness (aim 1) and to determine the preliminary efficacy of the hospice decision aid on decision quality, hospice knowledge, and values-concordance (aim 2). by testing the feasibility, acceptability, and preliminary efficacy of a novel hospice patient decision aid (ptda) in a diverse population of older adults, additionally the study will simultaneously explore barriers to ptda implementation in both an outpatient primary care and inpatient palliative care setting. the study will also gather sufficient pilot data to support a subsequent effectiveness/implementation trial and thus address the absence of quality of sdm interventions for end-of-life care decision-making.


Eligibility criteria:
inclusion criteria: * 65 or older. * at least one life-limiting illness or syndrome. exclusion criteria: * non-english speakers. * patients with cognitive impairments preventing ability to provide informed consent. * patients on isolation precautions due to resistant bacteria or impaired immune function.

Keywords: hospice end-of-life patient decision aid shared decision making
clinical trial of favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia

Conditions: Novel Coronavirus Pnuemonia

Summary: this study is a multi-centered, three-armed, randomized, double-blinded, controlled study, namely, the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group (combined group), the oral trial drug favipiravir tablets group (pirovir group), and the oral placebo treatment group (control group). the total number of enrolled cases in this study was set at 150. during the treatment, the clinical data of the subjects were collected, the changes of viral load and biochemical indicators were detected, and the outcome of the subjects was monitored. the main indicators of efficacy include improvement or recovery of respiratory symptoms and viral nucleic acid shedding. the rate of progression to severe disease, duration of fever, peripheral blood index and improvement time of pulmonary imaging were the secondary indicators to evaluate the efficacy. statistical analysis was performed at the middle and final stages of the study to evaluate the efficacy and safety of favipiravir tablets combined with chloroquine phosphatetablets tablets in the treatment of novel coronavirus pneumonia.


Eligibility criteria:
inclusion criteria: * male and female, 18-75 years old * patients previously diagnosed with novel coronavirus pneumonia: the course of illness is no more than 14 days; if the course of the disease was more than 14 days, patient meets one of the following conditions can also be included in the group: (1) no apparent absorption or progression of chest radiograph was observed within 7 days; (2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) test for viral nucleic acid positive within 3 days. * informed consent should be signed by the participate or an authorized agent * agree to clinical samples collection * female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age do not become pregnant exclusion criteria: * severe vomiting or difficulty ingesting medication * woman who are pregnant or during lactation * patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody specific antiviral drugs three days before enrollment * cases of respiratory failure requiring mechanical ventilation * shock * combined with other organ failure and requires icu care * clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission
investigating the neural mechanisms of repetitive brain stimulation with invasive and noninvasive electrophysiology in humans

Conditions: Major Depressive Disorder; Epilepsy

Summary: transcranial magnetic stimulation (tms) is an effective treatment for depression, but clinical outcome is suboptimal, partially because investigators are missing biologically-grounded brain markers which show that tms is modifying activity at the intended target in the brain. the goal of this proposal is to characterize the key markers of the brain's response to repeated doses of tms with high resolution using invasive brain recordings in humans, and relate these brain markers to noninvasive recordings. these markers will improve the understanding of tms and can be used to optimize and enhance clinical efficacy for depression and other psychiatric disorders.

repetitive transcranial magnetic stimulation (rtms) is an effective treatment for major depressive disorder, but remission rates are 20-40%, and ideal stimulation parameters are unknown. rtms is thought to work by changing the synaptic strength of neurons. the ability of the brain to make these changes is referred to as plasticity. rtms-induced changes are thought to build with successive treatment sessions, a process referred to as metaplasticity. while both plasticity and metaplasticity are well-established in single cell physiology, relevance to rtms in humans remains unknown. to improve clinical efficacy, the investigators need to understand 1) the neural response to a single rtms session (plasticity), 2) the neural response to repeated daily rtms sessions (metaplasticity), and 3) whether computational models of plasticity based on single-cell physiology apply to human patients receiving rtms for depression. goals of the study are to 1) establish a detailed mechanistic understanding of the brain changes during current rtms treatment; 2) identify clinically meaningful electrophysiological biomarkers for rtms treatment; 3) establish a computational model to help predict both brain and clinical changes.

Eligibility criteria:
inclusion criteria: * men and women, ages 18 to 65 * medication-refractory epilepsy requiring phase ii monitoring * must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent * no current or history of major neurological disorders other than epilepsy exclusion criteria: * those with a contraindication for mris (e.g. implanted metal) * any unstable medical condition * neurological or uncontrolled medical disease * active substance abuse * currently pregnant or breastfeeding